

14th July, 2016

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref. : Scrip Code No. : 532526
--	---

**Sub. Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015:
Company's site at Naroda and its subsidiary, Carbogen Amcis AG's sites at Aarau
and Neuland in Switzerland successfully Pass USFDA Inspection**

Dear Sir,

With reference to the captioned subject, we are happy to inform that the Company's wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA Inspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment Inspection Report (EIR) for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA.


Additionally, the company's site at Naroda had also successfully completed USFDA Inspection and received the Establishment Inspection Report (EIR) for the same.

Kindly take this on your record.

Thanking you.

Yours faithfully,
For Dishman Pharmaceuticals and Chemicals Limited


**Shrima Dave
Compliance Officer**



Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329